Skip to main content
Triangle logo TriangleGet started

Biospecimen Collection (NCT07718672)

Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer: a one-minute explainerNCT077186721 min

Biospecimen Collection trial for Early Stage Lung Non-Small Cell Carcinoma (NCT07718672). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with early-stage, biopsy-confirmed non-small-cell lung cancer, T1–3 without nodal involvement, who qualify for stereotactic radiation. Known EGFR or ALK mutations are excluded.

The idea: random assignment compares standard radiation planning with hotspots that deliver higher doses inside the tumor. Both groups receive one to five treatments over 1–11 days. Researchers compare local tumor control and side effects. Blood tests and scans track outcomes; lymph-node sampling may be needed.

This phase 2 study plans 200 patients. Mark Farrugia leads at Roswell Park in Buffalo, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.